(VIANEWS) – Knight Transportation (KNX), Texas Roadhouse (TXRH), RadNet (RDNT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Knight Transportation (KNX)
14.1% sales growth and 3.07% return on equity
Knight-Swift Transportation Holdings Inc., together with its subsidiaries, provides truckload transportation services in the United States and Mexico. The company operates through three segments: Trucking, Logistics, and Intermodal. Its trucking services include irregular route, dedicated, refrigerated, flatbed, expedited, dry van, drayage, and cross-border transportation of various products, goods, and materials. The company also provides logistics and intermodal services, such as brokerage, intermodal, and certain logistics; freight management; and non-trucking services. In addition, it offers various support services, including repair and maintenance shop services, warranty, insurance, and equipment leasing; and trailer parts manufacturing services, as well as engages in the driving academy activities. The company operates a total of 18,877 tractors, which comprises 16,432 company-owned tractors and 2,445 independent contractor tractors, as well as 58,315 trailers; and 643 tractors and 9,862 intermodal containers. It serves retail, food and beverage, consumer products, paper products, transportation and logistics, housing and building, automotive, and manufacturing industries. Knight-Swift Transportation Holdings Inc. was founded in 1989 and is headquartered in Phoenix, Arizona.
Earnings Per Share
As for profitability, Knight Transportation has a trailing twelve months EPS of $1.34.
PE Ratio
Knight Transportation has a trailing twelve months price to earnings ratio of 36.51. Meaning, the purchaser of the share is investing $36.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.07%.
2. Texas Roadhouse (TXRH)
12.2% sales growth and 28.71% return on equity
Texas Roadhouse, Inc., together with its subsidiaries, operates casual dining restaurants in the United States and internationally. The company operates and franchises Texas Roadhouse and Bubba's 33 restaurants. As of December 29, 2020, it operated 537 domestic restaurants and 97 franchise restaurants. Texas Roadhouse, Inc. was founded in 1993 and is based in Louisville, Kentucky.
Earnings Per Share
As for profitability, Texas Roadhouse has a trailing twelve months EPS of $4.53.
PE Ratio
Texas Roadhouse has a trailing twelve months price to earnings ratio of 32.81. Meaning, the purchaser of the share is investing $32.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.71%.
3. RadNet (RDNT)
12.1% sales growth and 4.65% return on equity
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Earnings Per Share
As for profitability, RadNet has a trailing twelve months EPS of $0.05.
PE Ratio
RadNet has a trailing twelve months price to earnings ratio of 970. Meaning, the purchaser of the share is investing $970 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.65%.
4. Verra Mobility Corporation (VRRM)
7% sales growth and 17.48% return on equity
Verra Mobility Corporation provides smart mobility technology solutions and services in the United States, Canada, and Europe. It operates through two segments, Government Solutions and Commercial Services. The Government Solutions segment offers automated safety solutions, including services and technologies that enable photo enforcement through road safety camera programs, which detects and process traffic violations related to red light, speed, school bus, and city bus lanes. This segment serves municipalities, counties, school districts, and law enforcement agencies. The Commercial Services segment provides automated toll and violations management, and title and registration solutions to rental car companies, fleet management companies, and other large fleet owners. The company is headquartered in Mesa, Arizona.
Earnings Per Share
As for profitability, Verra Mobility Corporation has a trailing twelve months EPS of $0.36.
PE Ratio
Verra Mobility Corporation has a trailing twelve months price to earnings ratio of 65.25. Meaning, the purchaser of the share is investing $65.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.48%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.4%, now sitting on 817.31M for the twelve trailing months.
Volume
Today’s last reported volume for Verra Mobility Corporation is 782699 which is 27.33% below its average volume of 1077110.
Yearly Top and Bottom Value
Verra Mobility Corporation’s stock is valued at $23.49 at 01:22 EST, below its 52-week high of $25.57 and way above its 52-week low of $16.22.
5. Jazz Pharmaceuticals plc (JAZZ)
6.8% sales growth and 12.16% return on equity
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Jazz Pharmaceuticals plc has a trailing twelve months EPS of $6.1.
PE Ratio
Jazz Pharmaceuticals plc has a trailing twelve months price to earnings ratio of 18.69. Meaning, the purchaser of the share is investing $18.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.16%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Jazz Pharmaceuticals plc’s EBITDA is 41.06.
